Literature DB >> 17228120

Recovery of total I-131 activity within focal volumes using SPECT and 3D OSEM.

Kenneth F Koral1, Anastasia Yendiki, Yuni K Dewaraja.   

Abstract

We experimentally investigated the SPECT recovery of I-131 activity in multiple spheres located simultaneously at different locations within a cylindrical phantom that had an elliptical cross section. The sphere volumes ranged from 209 cc down to 4.2 cc. A Prism 3000 camera and two types of parallel-hexagonal-hole collimation were employed: high energy (HE) and ultra high energy (UHE). Using appropriately-different 3D models of the point source response function for the two types of collimation, approximately the same recovery of activity could be achieved with either collimation by 3D OSEM reconstruction. The recovery coefficient was greater with no background activity in the phantom by 0.10, on average, compared to that with background. In the HE collimation case, the activity recovery was considerably better for all volumes using 3D OSEM reconstruction than it had been in the past using 1D SAGE reconstruction. Recovery-coefficient-based correction in a simulated patient case involving spherical tumours moderately improved the activity estimates (average error reduced from 14% to 9% for UHE collimation, and from 15% to 11% for HE collimation). For a test case with HE collimation, increasing the projection-image sampling density while decreasing the image voxel size increased the recovery coefficient by 0.075 on average, and, if used in a full set of calibration measurements of recovery coefficient versus volume, might lead to further improvement in accuracy for the patient case.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228120     DOI: 10.1088/0031-9155/52/3/017

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  13 in total

1.  Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Authors:  Peter L Roberson; Lauren B Smith; Meredith A Morgan; Matthew J Schipper; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2017-10-30       Impact factor: 3.099

2.  MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy.

Authors:  Yuni K Dewaraja; Eric C Frey; George Sgouros; A Bertrand Brill; Peter Roberson; Pat B Zanzonico; Michael Ljungberg
Journal:  J Nucl Med       Date:  2012-06-28       Impact factor: 10.057

3.  Improved quantitative 90 Y bremsstrahlung SPECT/CT reconstruction with Monte Carlo scatter modeling.

Authors:  Yuni K Dewaraja; Se Young Chun; Ravi N Srinivasa; Ravi K Kaza; Kyle C Cuneo; Bill S Majdalany; Paula M Novelli; Michael Ljungberg; Jeffrey A Fessler
Journal:  Med Phys       Date:  2017-10-28       Impact factor: 4.071

4.  Regularized reconstruction in quantitative SPECT using CT side information from hybrid imaging.

Authors:  Yuni K Dewaraja; Kenneth F Koral; Jeffrey A Fessler
Journal:  Phys Med Biol       Date:  2010-04-14       Impact factor: 3.609

5.  Factors affecting the repeatability of gamma camera calibration for quantitative imaging applications using a sealed source.

Authors:  N Anizan; H Wang; X C Zhou; R L Wahl; E C Frey
Journal:  Phys Med Biol       Date:  2015-01-16       Impact factor: 3.609

6.  131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling.

Authors:  Yuni K Dewaraja; Matthew J Schipper; Peter L Roberson; Scott J Wilderman; Hanan Amro; Denise D Regan; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  J Nucl Med       Date:  2010-06-16       Impact factor: 10.057

7.  Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study.

Authors:  Yuni K Dewaraja; Scott J Wilderman; Kenneth F Koral; Mark S Kaminski; Anca M Avram
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

8.  Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters.

Authors:  Peter L Roberson; Scott J Wilderman; Anca M Avram; Mark S Kaminski; Matthew J Schipper; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2013-10-08       Impact factor: 3.099

9.  Development and Validation of RAPID: A Patient-Specific Monte Carlo Three-Dimensional Internal Dosimetry Platform.

Authors:  Abigail E Besemer; You Ming Yang; Joseph J Grudzinski; Lance T Hall; Bryan P Bednarz
Journal:  Cancer Biother Radiopharm       Date:  2018-04-25       Impact factor: 3.099

10.  Prediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activity.

Authors:  Matthew J Schipper; Kenneth F Koral; Anca M Avram; Mark S Kaminski; Yuni K Dewaraja
Journal:  Cancer Biother Radiopharm       Date:  2012-09       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.